Palatin Technologies, Inc. — Form 10-Q Summary
Business context and reporting period. Palatin is a development-stage biopharmaceutical company focused on peptide therapeutics. Its lead clinical program is bremelanotide for female sexual dysfunction (FSD); other programs include PL-3994 and melanocortin-receptor candidates. This report covers the fiscal quarter and six months ended December 31, 2012, with comparisons to the periods ended December 31, 2011.
Financial performance and position
| Metric | Three months ended Dec. 31, 2012 | Six months ended Dec. 31, 2012 | Prior comparable period |
|---|---|---|---|
| Revenue | $6,555 | $10,361 | $11,492 and $38,709, respectively |
| Operating expenses | $3.45 million | $6.85 million | $3.71 million and $7.11 million, respectively |
| Operating loss | $3.44 million | $6.84 million | $3.70 million and $7.07 million, respectively |
| Net loss | $1.68 million | $12.13 million | $2.62 million and $5.98 million, respectively |
| Basic and diluted loss per share | $0.02 | $0.14 | $0.08 and $0.17, respectively |
Revenue consisted entirely of AstraZeneca collaboration reimbursements and compensation, making revenue highly concentrated and modest relative to operating costs. The company reported no meaningful product-sales margin; the filing does not provide a clear gross-margin measure.
- Cash and liquidity: Cash and cash equivalents were $32.85 million at December 31, 2012, versus $3.83 million at June 30, 2012. Current assets were $33.23 million and current liabilities $2.05 million. Restricted cash of $350,000 at June 30 was no longer reported at year-end.
- Cash flow: Operating activities used $5.32 million in the six months, compared with $6.95 million in the prior-year period. Investing activities used $17,154. Financing activities provided $34.36 million, principally from the July 2012 private placement. Ending cash was $32.85 million.
- Debt and liabilities: Total liabilities were $2.11 million, including capital lease obligations of about $31,000 and deferred rent of $54,000. The filing reports no significant conventional borrowing.
- Equity financing and share count: The July 3, 2012 private placement generated $35.0 million gross and $34.4 million net proceeds. At December 31, 38.95 million common shares were outstanding; the filing reports a six-month weighted-average share count of 89.05 million, affected by warrants included in the loss-per-share calculation.
Material changes and unusual items
- Six-month revenue declined to $10,361 from $38,709. Research and development expense was $4.79 million, down from $4.98 million; general and administrative expense was $2.06 million, down from $2.13 million.
- Six-month net loss increased to $12.13 million from $5.98 million, largely because of a $7.07 million non-cash expense from an increase in the fair value of certain warrants before their reclassification to equity. This was partly offset by a $1.75 million tax benefit from selling New Jersey net operating loss carryforwards.
- Quarterly net loss improved year over year, with a $1.75 million tax benefit in both quarters. In the six-month comparison, the prior-year period did not include the warrant fair-value charge.
- The July financing included Series A warrants for up to 31.99 million shares and Series B warrants for up to 35.49 million shares, exercisable at $0.01 per share and expiring ten years after issuance. The warrants include ownership blockers and provisions that may require redemption in certain company transactions. QVT-affiliated purchasers also received specified financing rights and restrictive-covenant protections.
- General R&D costs fell partly after staffing reductions and closure of the research laboratory when its lease expired in July 2012.
Outlook, management commentary, and risks
- Palatin reported positive top-line Phase 2B bremelanotide results on November 8, 2012, including statistically significant results for the primary and key secondary endpoints. The trial involved 327 pre-menopausal women. Management reported the treatment was generally well tolerated; common treatment-emergent events included flushing, nausea, and vomiting, and no serious adverse events were attributed to treatment.
- The company requested an FDA end-of-Phase 2 meeting. Phase 3 activities were anticipated to begin in the second half of calendar 2013, conditional on FDA discussions and further development decisions.
- Management believed existing cash would fund planned operations, including completion of Phase 2B results analysis and the FDA meeting, through at least calendar 2013. The company said Phase 3 would require significant additional capital and that current resources would not fund all trials needed for product approval.
- Palatin expected continued losses for at least the next few years and said funding beyond calendar 2013 might not be available on acceptable terms or at all. Failure to obtain financing or collaborators could force earlier partnering, licensing, or disposal of program rights on less favorable terms, or curtailment of programs.
- Development, clinical and regulatory outcomes, manufacturing, intellectual-property protection, commercialization, and access to capital remain key risks. Management stated that quarterly results may not indicate full-year results and expected a significant loss for the fiscal year ending June 30, 2013.
- All reported revenue in the periods presented came from AstraZeneca. AstraZeneca’s obesity-related candidates were in preclinical evaluation; Palatin remained eligible for specified milestone payments and royalties under the agreement.
Important facts for investors to verify
- FDA feedback, required trial design, timing, and cost for Phase 3 bremelanotide development.
- Whether Palatin can secure sufficient funding beyond calendar 2013 and the potential terms and dilution of additional financing.
- The scope and practical effect of the low-exercise-price warrants, transaction-related redemption provisions, and related share-count disclosures.
- Continuing cash burn, remaining runway, and how planned spending across bremelanotide, PL-3994, and other programs may change.
- Dependence on AstraZeneca and the timing and likelihood of any future milestones, royalties, or collaboration revenue.